Boston Scientific falls on FDA warning, Guidant results

January 28, 2006 at 11:34 am · Filed under For Investors

Will the Boston Scientific/Guidant/Abbott deal close? The market seems to think there’s a good chance it won’t. If it doesn’t, look for J&J to make a reduced-value offer for Guidant (under $70/share). If it does, look for J&J and Abbott to benefit most (after Guidant stockholders, of course) from the over-priced deal. Boston Scientific shareholders comes out on the losing end of this deal either way in my estimation.

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • SphereIt
  • TailRank
  • Technorati
Sphere: Related Content

RSS feed for comments on this post · TrackBack URL

Leave a Comment

You must be logged in to post a comment.